Description
GenJet™ DNA In Vitro Tranfection Reagent for LNCap is pre-optimized for transfecting LNCap cells. LNCap cells are a cell line of human cells commonly used in the field of oncology. LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. They are adherent epithelial cells growing in aggregates and as single cells.
Refer to the following optimal transfection conditions for maximal transfection efficiency on LNCap cells. GenJet™ reagent, 1.0 ml, is sufficient for 300 to 600 transfections in 24 well plates or 50 to 100 transfections in 6 well plates.
Summary of Optimal Transfection Conditions:
Confluence on the day of transfection
|
95% |
Cell culture conditions |
DMEM with 4.5 g/L glucose, 10% FBS
|
GenJet™ (µl) : DNA (µg) Ratio |
3:1 |
Diluent for DNA and Transfection Reagent
|
Serum-free DMEM with 4.5 g/L glucose
|
Incubation Time to Form GenJet™/DNA Complex |
15 minutes at RT |
Presence of Serum/Antibiotics during Transfection |
Yes |
Change Medium After Transfection |
No |
Maximal Efficiency |
48 hours |
Transfection Results:
Reporter Gene
|
EGFP |
Plasmid
|
pEGFP-N3 (CMV promoter)
|
Efficiency (GFP %) |
80% |
Storage Condition
Store at 4 °C. If stored properly, the product is stable for 12 months or longer
GenJet™ reagent is optimized for LNCap cells. LNCap cells were grown per ATCC recommended culture medium and transfected with pEGFP-N3 by GenJet™ (Ver. II). The efficiency was checked 48 hours post transfection
Data Sheet